Journal
MODERN PATHOLOGY
Volume 22, Issue 1, Pages 43-49Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/modpathol.2008.140
Keywords
HMGA2; pancreatic ductal adenocarcinoma; oncogene; immunoreactivity
Categories
Funding
- NCI NIH HHS [R29 CA076130-05, R01 CA092339, R01 CA092339-01A1] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA092339, R29CA076130] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma is a highly aggressive, lethal human malignancy that continues to elude successful treatment. Although most patients present with metastatic disease, the molecular pathways that underlie tumor progression and metastases are poorly understood. The high mobility group A2 (HMGA2) protein is an architectural transcription factor that has recently been implicated in the development and progression of malignant tumors. Here, we examined HMGA2 gene expression in pancreatic ductal adenocarcinoma to determine if it could be a marker for more advanced disease. By real time quantitative RT-PCR, we showed a marked increase in HMGA2 mRNA in two of three cultured pancreatic ductal adenocarcinoma cell lines compared to normal pancreatic tissue. Using tissue microarrays generated from 124 pancreatic ductal adenocarcinoma cases, we also assessed HMGA2 protein levels by immunohistochemical analysis. We found that HMGA2 nuclear immunoreactivity correlates positively with lymph node metastases and high tumor grade. Our results support a role for HMGA2 in the progression of pancreatic ductal adenocarcinoma and suggest that it could be a useful biomarker and rational therapeutic target in more advanced disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available